Table 5.

Trade-offs (marginal rates of substitution) and marginal willingness-to-pay estimates for MMNL model

Marginal willingness-to-pay estimates		Mean	95% CI	Interpretation
Respondent characteristic	Attribute
Respondents with low-income ≤ AU$87,999 per year	Risk of recurrence at 3 years	– 794.032	−1745.15 to 740.70	Respondents with lower income were, on average, willing to pay an extra AU$795 (95% CI – AU$741 to AU$1745) per year for each 1% reduction in their absolute risk of recurrence at 3 years with adjuvant immunotherapy
Respondents with high-income ≥ AU$88,000 per year	Risk of recurrence at 3 years	– 2189.55	– 4571.05 to 1650.90	Respondents with higher income were, on average, willing to pay an extra AU$2190 (95% CI – AU$1651 to AU$4571) for each 1% reduction in their absolute risk of recurrence at 3 years with adjuvant immunotherapy
Respondents with low-income ≤ AU$87,999 per year	Risk of a fatal adverse event (AE)	– 1530.73	– 8416.53 to 1527.40	Respondents with lower income were, on average, willing to pay AU$1531 (95% CI – AU$1527 to AU$8417) for a 1% lower chance of fatal AE
Respondents with high-income ≥ AU$88,000 per year	Risk of a fatal AE	– 4265.71	– 13,997.35 to 3484.34	Respondents with higher income were, on average, willing to pay AU$4266 (95% CI – AU$3484 to AU$13,997) for a 1% lower chance of fatal AE
Marginal rates of substitution estimates
Risk of recurrence at 3 years $÷$ risk of a permanent AE		– 4.42	– 23.41 to 10.44	Respondents were willing to accept an additional 4% chance of a permanent AE to reduce their absolute risk of recurrence at 3 years by 1% (95% CI – 10.44 to 23.41)
Risk of a fatal AE $÷$ risk of recurrence at 3 years		– 1.81	– 34.54 to 12.35	Respondents were willing to accept an additional 2% chance of recurrence at 3 years to lower their chance of a fatal AE by 1% (95% CI – 12.35 to 34.54)